Expanding the COL7A1 Mutation Database: Novel and Recurrent Mutations and Unusual Genotype – Phenotype Constellations in 41 Patients with Dystrophic Epidermolysis Bullosa  by Kern, Johannes S. et al.
Expanding the COL7A1 Mutation Database: Novel
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Dystrophic epidermolysis bullosa (DEB), a heterogeneous hereditary skin disorder characterized by trauma-
induced blistering and scarring, affects thousands of families worldwide. The clinical manifestations extend
from minor nail dystrophy to severe life-threatening blistering, making early molecular diagnosis and
prognostication of utmost importance for the affected families. DEB is caused by mutations in the COL7A1 gene
encoding collagen VII in the skin. Molecular diagnostics and genotype–phenotype correlations in DEB remain
complex owing to the gene structure, large variety of mutations, high rate of novel mutations, complex protein
structure and assembly, and the heterogeneity of phenotypes. Here, we report an efficient strategy for COL7A1
mutation detection using direct automated DNA sequencing and implementation of software tools. With this
approach, COL7A1 mutations of 41 DEB families were disclosed. Twenty-four mutations were novel and two
recurrent. Elucidation of biological consequences of the mutations helped define disease mechanisms, but also
revealed several unusual genotypic and/or phenotypic constellations, which impeded the diagnostics and
prognostication. In addition, the studies disclosed a de novo mutation in recessive DEB and two new
polymorphisms in the COL7A1 gene.
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INTRODUCTION
Dystrophic epidermolysis bullosa (DEB) is a clinically
heterogeneous heritable skin disorder, characterized by
blistering of the skin and mucous membranes following
minor trauma, and with a broad range of clinical severity
(Fine et al., 1999; Bruckner-Tuderman, 2002). All forms are
caused by mutations in COL7A1, the gene coding for colla-
gen VII (Hovnanian et al., 1992). This collagen, the major
component of the anchoring fibrils, is reduced or missing in
DEB skin, and the anchoring fibrils are morphologically
altered or absent and functionally defective (Bruckner-Tuderman
et al., 1999). Notably, the full spectrum of gene mutations
and the molecular mechanisms leading to these visual and
functional alterations still remain elusive, despite significant
scientific efforts.
Worldwide, DEB affects thousands of families. Therefore,
efficient COL7A1 mutation detection is urgently needed for
precise diagnosis, prognostication, genetic counseling and
reliable prenatal diagnosis, and, importantly, for identifica-
tion of suitable candidates for future gene therapy trials.
COL7A1 is located within the 3p21 region and spans over
30.5 kb. It shares structural features with other collagen genes
and consists of 118 small exons and small introns. To date,
more than 200 different mutations have been reported, but
very few recurrent mutations or hot spots are known (Uitto,
2004). Instead, the mutations are distributed over the entire
gene (Jarvikallio et al., 1997; Uitto et al., 2002), a fact
that renders COL7A1 screening technically tedious, time
consuming, and expensive.
One aim of the present study was to establish efficient
COL7A1 mutation detection by direct sequencing. This
strategy was chosen owing to its high sensitivity and
specificity, and recently decreased costs. Another objective
was digital analysis and management of the high amount of
sequencing data that would be produced. Using these
technical advances, COL7A1 mutations in 41 DEB patients
were disclosed and their genotype–phenotype correlations
delineated.
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RESULTS
Clinical findings
Forty-one DEB patients with mechanobullous lesions of the
skin and/or mucous membranes and scarring were included
in the present investigation. Clinical diagnosis, expression of
collagen VII in the skin, and the morphology of the anchoring
fibrils are summarized in Table 1. In two DEB families, the
pedigree pattern was autosomal dominant (patients 39 and
41); the other families showed autosomal recessive inheri-
tance pattern or cases were sporadic. Nineteen patients had
the severe Hallopeau–Siemens subtype of RDEB (HS-RDEB).
Twelve individuals with non-Hallopeau–Siemens RDEB pre-
sented with different degrees of blistering, but without
pseudosyndactyly or fusion of the digits. Patient 2, a 52-
year-old male with a similarly affected younger brother had
localized oral, esophageal, and anal blistering with dyspha-
gia and an enterostenosis, but practically no skin blisters. Six
patients were regarded as non-classified RDEB (patients 13,
14, and 16–19), as no detailed clinical and morphologic data
were available.
COL7A1 mutation survey
Using the ‘‘priority strategy’’ for mutation detection, 74
mutated alleles were disclosed in 41 patients (Table 1).
Based on the pedigrees, 78 mutated alleles were predicted
and, therefore, the detection sensitivity was 94.8%. The
screening strategy based on the number and frequency
of known mutations proved very efficient: in the exons
on the ‘‘high priority’’ plate, already 73% of the mutant
alleles were identified. Of the 44 different mutations
disclosed in this study, 24 were novel: four insertion/
deletions, five splicing, 11 missense, and four nonsense
mutations (Table 1). All novel insertion/deletion mutations
led to the formation of downstream premature termination
codons (PTCs). The frequent mutation 425A4G was found in
nine (12.16%) and R1933X in five (6.75%) alleles in
unrelated individuals.
Intronic mutations
Five patients (patients 3, 9, 24, 36, and 37) had novel intronic
mutations. The 10-year-old patient 3 with a relatively mild,
generalized non-Hallopeau–Siemens RDEB was homozygous
for the mutation 3550þ2T4G in intron 26. Antigen
mapping showed the presence of collagen VII in the skin,
correlating with the clinical presentation. Reverse transcrip-
tase-polymerase chain reaction (RT-PCR) analysis of kerati-
nocyte mRNA and direct sequencing of the transcript
demonstrated that the mutation led to abolition of the normal
donor splice site and activation of an upstream cryptic splice
site within exon 26. This resulted in in-frame skipping of the
last 13 codons of exon 26, corresponding to amino acids
1171–1183, located close to the C-terminal end of the amino-
terminal non-collagenous domain of procollagen VII. The
mutations 35513T4G in intron 26 and 2314þ 5G4A in
intron 17 were identified in HS-RDEB patients 36 and 37,
respectively, in compound heterozygosity with null muta-
tions. As material for verification on RNA level was not
available, splicing prediction software (www.cbs.dtu.dk/
services/NetGene2/ and www.fruitfly.org/seq_tools/splice.
html) was used to evaluate the consequences. Both mutations
were predicted to decrease the confidence coefficients of the
respective splice sites and, therefore, we presume that they
are functionally relevant. In addition, both mutations were
absent in 100 control chromosomes. A third intronic
mutation, 38322A4G, which affects the conserved accep-
tor splice site of intron 30, was identified in patient 9; it
occurred in combination with the glycine substitution
G1347W. The intronic mutation of patient 24 is described
below.
Glycine substitutions alter protein folding
Of the 10 novel glycine substitutions found here, G2689R
was investigated on protein level because of the particular
phenotype of patient 2 (see above and Figure 1a). The glycine
substitution G2689R at the C-terminal end of the triple helix
of collagen VII was a consequence of the substitution
8065G4A in exon 109 in patient 2. The second mutation,
6527insC in exon 80, results in a PTC and, therefore, the
patient is functionally homozygous for the glycine substitu-
tion. Thermal stability assays of the mutated procollagen VII
showed the helix-to-coil transition temperature to be
decreased to 33–351C, instead of the normal value of
39–411C. Limited pepsin digestion revealed reduced stability
of the triple helix (Figure 1b). This implies abnormal protein
folding, which renders the mutated protein sensitive to
nonspecific degradation by cellular and tissue proteinases.
Correspondingly, the quantity of collagen VII in the skin was
reduced, as shown with antigen mapping (Figure 1c and d).
Non-glycine amino-acid substitutions
Patients 1 and 7 with non-HS-RDEB, who were related, had
the mutation E2059G. Patient 1 was homozygous for the
mutation, patient 7 hemizygous or functionally homozygous.
Immunofluorescence staining of the patients’ keratinocytes
and immunoblotting of the mutant collagen VII indicated
lower production of procollagen VII in the cells, although the
triple-helix stability of the mutated collagen was not altered.
The proline substitution P1458L, a manifestation of the
sequence variant 4373C4T, was found in patient 24. The
variant was not found in normal controls. In addition,
secondary protein structure prediction (http://npsa-pbil.
ibcp.fr, http://bioinf.cs.ucl.ac.uk/psipred/) indicated that the
mutation caused significant structural changes in collagen
VII, from coil to sheet, arguing for a functional relevance of
this variant. Sequencing of the entire COL7A1 gene revealed
two further mutations: 426þ 1G4A and 1474del11. P1458L
and 1474del11 were inherited in cis from the unaffected
mother and 426þ 1G4A from the father. We carefully
examined the mother of patient 24, and found no clinical sign
that could be associated with epidermolysis bullosa. RT-PCR
analysis of keratinocyte mRNA showed that the mutation
426þ1G4A in intron 3 generated two aberrant transcripts:
out-of-frame skipping of exon 3 and insertion of intron 3,
both of which led to a downstream PTC. Taken together, the
PTC mutations, but not the amino-acid substitution, were
causally relevant in this case.
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Table 1. Phenotypes and COL7A1 genotypes of families analyzed and novel mutations (bold)
Mutation 1 Mutation 2
Patient Diagnosis COLVII1 Region cDNA Protein/consequence Region cDNA Protein/consequence
1 nHS-RDEB k Ex 73 6176A4G E2059G Ex 73 6176A4G E2059G
2 nHS-RDEB k Ex 80 6527insC PTC Ex 109 8065G4A G2689R
3 nHS-RDEB k IVS26 3550+2T4G In-frame deletion IVS26 3550+2T4G In-frame deletion
4 nHS-RDEB k Ex 4 497dupA PTC Ex 42 4474G4A G1492R
5 nHS-RDEB k Ex 51 4846G4A G1616R Ex 51 4846G4A G1616R
6 nHS-RDEB k Ex 95 7344G4A Splice site Ex 103 7723G4A G2575R
7 nHS-RDEB k Ex 51 4894C4T R1632X Ex 73 6176A4G E2059G
8 nHS-RDEB k Ex 58 5155G4C G1719R Ex 58 5155G4C G1719R
9 nHS-RDEB k IVS30 38322A4G Splice site Ex 34 4039G4T G1347W
10 nHS-RDEB NA Ex 3 425A4G PTC Ex 74 6205C4T R2069C
11 nHS-RDEB NA Ex 3 425A4G PTC Ex 95 7344G4A Splice site
12 nHS-RDEB AFk Ex 45 4564G4C G1522R ND
13 RDEB NA Ex 3 425A4G PTC Ex 61 5345G4T G1782V
14 RDEB NA Ex 3 425A4G PTC Ex 94 7238G4A G2413E
15 HS-RDEB2 AF Ex 72 5944_5945 delGGinsTA PTC Ex 72 5944_5945 delGGinsTA PTC
16 RDEB NA Ex 70 5797C4T R1933X Ex 73 6081delC PTC
17 RDEB k Ex 1 62dupT PTC ND
18 RDEB k Ex 110 8209G4C G2737R ND
19 RDEB k Ex 70 5797C4T R1933X ND
20 HS-RDEB AFk Ex 80 6508C4T Q2170X Ex 80 6508C4T Q2170X
21 HS-RDEB2  Ex 13 1732C4T R578X Ex 13 1732C4T R578X
22 HS-RDEB  Ex 70 5797C4T R1933X Ex 70 5797C4T R1933X
23 HS-RDEB  Ex 3 425A4G PTC Ex 3 425A4G PTC
24 HS-RDEB3  IVS3 426+1G4A PTC Ex 11 1474del11 PTC
25 HS-RDEB /AF Ex 38 4249delG PTC Ex 70 5797C4T4 R1933X
26 HS-RDEB  Ex 3 425A4G PTC Ex 86 6781C4T R2261X
27 HS-RDEB  Ex 3 425A4G PTC Ex 34 4027C4T R1343X
28 HS-RDEB  Ex 105 7828C4T R2610X Ex 105 7828C4T R2610X
29 HS-RDEB2  Ex 5 553C4T R185X Ex 5 553C4T R185X
30 HS-RDEB  Ex 13 1732C4T R578X Ex 13 1732C4T R578X
31 HS-RDEB NA Ex 4 497dupA PTC IVS51 4899+1G4A Splice site
32 HS-RDEB  Ex 15 1930delC PTC Ex 15 1930delC PTC
33 HS-RDEB  Ex 20 2629C4T Q877X Ex 80 6508C4T Q2170X
34 HS-RDEB  IVS5 682+1G4A PTC IVS5 682+1G4A PTC
35 HS-RDEB  Ex 3 425A4G PTC Ex 19 2527C4T R843X
36 HS-RDEB  IVS26 35513T4G Splice site Ex 51 4894C4T R1632X
37 HS-RDEB  IVS5 682+1G4A PTC IVS17 2314+5G4A Splice site
38 DDEB NA Ex 73 6101G4A3 G2034E
39 DDEB + Ex 75 6227G4A G2076D
40 DDEB + Ex 87 6899A4G Skipping of exon 87
41 DDEB NA Ex 73 6127G4A G2043R
DDEB: dominant DEB; HS-RDEB: Hallopeau–Siemens recessive DEB; NA: not available; ND: not determined; nHS-RDEB non-Hallopeau–Siemens recessive
DEB; RDEB recessive dystrophic EB not specified.
1Collagen VII: IIF – + present, k reduced,  absent; EM – AFk anchoring fibrils reduced, AF anchoring fibrils absent.
2Prenatal diagnosis in patient’s family performed.
3In patient 24, in addition to the mutations listed in the table, the sequence variant 4373C4T was disclosed (see Results).
4De novo mutation.
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R1933X, mutational hotspot, and de novo mutation
In the DNA of the 17-year-old patient 25 with generalized
HS-RDEB, the mutations 4249delG and R1933X were
disclosed. Unexpectedly, the father did not carry either
mutation. The patient records indicated that paternity had
been confirmed in 1994, in context of prenatal diagnosis for
II-6 (Figure 2). Haplotype analysis performed at that time
showed that the fetus (II-6 in Figure 2) had inherited the same
haplotypes as patient 25, and it was therefore assumed that it
would be affected. However, parallel electron microscopy
studies of skin biopsy of the same fetus (II-6 in Figure 2)
suggested the unborn to be unaffected. Finally, a healthy
child was born. To demonstrate possible somatic mosaicism,
we analyzed DNA from different tissues by direct sequencing
and found the mutation in the patient’s leukocyte and buccal
swab DNA and keratinocyte mRNA. This broad distribution
argues against somatic mosaicism and for a de novo
mutational event in a single gamete.
Novel COL7A1 polymorphisms
In the course of the screening, two hitherto unpublished
polymorphisms were found in exon 27: the sequence variant
3560T4C led to amino-acid exchange V1187A (1% of
control chromosomes), and the sequence variant 3605G4A
to R1202H (2% of control chromosomes).
DISCUSSION
In this study, detection of COL7A1 mutations by the ‘‘priority
strategy’’ and direct sequencing turned out to be more
efficient, reliable and, with 94.8%, more sensitive than by
other approaches. In previous studies, protein truncation test
had a sensitivity of 58% and fluorescent chemical cleavage of
mismatch of 81% in COL7A1 screening (Whittock et al.,
1999). The two most often employed techniques to screen all
118 COL7A1 exons are conformation-sensitive gel electro-
phoresis (CSGE) (Mellerio et al., 1999; Gardella et al., 2002)
and denaturing high-performance liquid chromatography
(Pfendner et al., 2003). Conformation-sensitive gel electro-
phoresis was reported to have a sensitivity between 75 and
86% (Whittock et al., 1999; Gardella et al., 2002). Whittock
et al. achieved a sensitivity of 87% by combining: protein
truncation test, conformation-sensitive gel electrophoresis,
and fluorescent chemical cleavage of mismatch.
More than 10 years after the DEB-causing gene was
identified, the detection rate of novel mutations remains
constantly high, 24 of 44 different mutations in this study, and
has not changed significantly in studies published in recent
years (Whittock et al., 1999; Gardella et al., 2002). The splice
site mutation 425A4G, at the donor splice site of exon 3,
was the most frequent mutation in the present cohort; with
12.16% of alleles, its frequency was similar to data reported
by others (Murata et al., 2004; Csikos et al., 2005). Also,
R1933X was recurrent and, interestingly, had arisen de novo
in one German patient with recessive DEB. As such, an event
is rare in recessive diseases, this is an argument against a
common founder mutation and speaks for a mutational
hotspot, which is supported by the fact that the mutation is a
transition at a CpG dinucleotide.
Ten novel glycine substitution mutations in COL7A1 were
identified in this study. Nine of them were silent in the
heterozygous state and caused a disease phenotype when
inherited in trans with another COL7A1 mutation on the
other allele. In most cases, these led to mild-to-moderate
recessive DEB forms. These findings reinforce the point that
when a glycine substitution is found in sporadic cases, it
is important to search for further COL7A1 mutations
(Mallipeddi et al., 2003).
The biological consequences of glycine substitutions in
collagen VII can be manifold and perturb the formation and
functions of anchoring fibrils with different mechanisms. The
mutations G2006D, G2034R, and G2015E interfere with
protein folding and lead to intracellular accumulation of
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Figure 1. G2689R is associated with predominantly mucosal involvement
and leads to reduced stability of the triple helix of collagen VII. (a) Toenail
dystrophy, erosion, and crusting on the medial aspect of the fourth toe in
patient 2. (b) Extracts of normal keratinocytes (NHK) and keratinocytes of
patient 2 (P2) were subjected to limited pepsin treatment, and the digestion
products were identified with antibodies against the C-terminus of the
collagen VII triple helix. The digestion removed the globular domains of
procollagen VII and yield two bands: the triple helical domain (TH) and its
C-terminal half, the P1 fragment. Even under mild conditions, pepsin partially
cleaves the triple helix of collagen VII and generates two shorter triple-helical
fragments, each representing about one-half of the entire helix, the C-terminal
P1 and the N-terminal P2 fragment. Of these, only the P1 fragment was
visualized with the antibody employed. Lanes: (1) NHK without pepsin ();
(2) P2 keratinocytes without pepsin () show both a band corresponding to
procollagen VII (PCVII); (3) NHK with pepsin (þ ); and (4) P2 keratinocytes
with pepsin (þ ) show bands corresponding to TH and the P1 fragment.
Pepsin treatment of P2 procollagen VII resulted in increased generation of the
P1 fragment, indicating that G2689R decreased the stability of the triple helix.
(c) Indirect immunofluorescence (IIF) of normal skin with antibodies to the
C-terminus of collagen VII shows strong positive staining at the dermal–epi-
dermal junction. (d) Indirect immunofluorescence of the skin of patient 2
revealed a reduced collagen VII signal at the blister roof (*), showing that the
helix destabilization and susceptibility to tissue proteinases is relevant in the
skin in situ. Bar¼ 50mm.
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collagen VII (Bruckner-Tuderman et al., 1999). G2749R
caused incomplete folding of recombinantly produced
collagen VII and rendered it sensitive to proteinases (Chen
et al., 2002). The mutation G2623C prevented dimer
formation and thereby inhibited assembly of the anchoring
fibrils, possibly owing to the proximity to a critical binding
site for the carboxyl-terminal non-collagenous domain during
dimer formation (Brittingham et al., 2005). In spite of these
kinds of investigations, the genotype–phenotype correlations
of yet other glycine substitutions remain elusive, and the
underlying mechanisms are only beginning to emerge.
For example, in patient 2 of this study, the hemizygous
G2689R mutation led to an interesting phenotype:
mucosal involvement and nail dystrophy, but no skin blisters.
A similar phenotype has been described once before (Zimmer
et al., 2002) in a patient who also was hemizygous for a
glycine substitution, this time G2775S. Both G2689R and
G2775S are located in the very distal carboxyl-terminus of
the triple helical domain of collagen VII. Now we demon-
strate that destabilization of the triple helix underlies this
phenotype.
Missense mutations other than glycine substitutions are
rare in collagen VII. Here, the novel glutamic acid to glycine
substitution E2059G in exon 73 was present in patients 1 and
7 and correlated with a rather mild clinical phenotype.
Unlike R2008G, which caused intracellular accumulation of
procollagen VII (Chen et al., 2002), E2059G leads to reduced
levels of procollagen VII in the cells.
An intriguing constellation involving a non-glycine amino-
acid substitution was observed in the family of patient 24.
The sequence variant 4373C4T, leading to the substitution
P1458L, did not correlate with the patient’s severe HS-RDEB
phenotype. However, several lines of evidence spoke for the
pathogenic role of P1458L. First, proline residues at the Y
position of the Gly-X-Y repeat, as also is the case of proline
1458, are frequently hydroxylated and involved in stabiliza-
tion of collagen triple helix (Tasanen et al., 2000). Second,
data from controls’ screening and secondary protein structure
predictions indicated a pathogenic role. Third, another
proline-to-leucine mutation, P1669L, was reported to cause
pretibial RDEB in compound heterozygosity with a splice site
mutation (Gardella et al., 2002). In spite of these arguments,
P1458L turned out not to be disease causing in this case, as
full screening of COL7A1 revealed two other PTC mutations
in patient 24 and his parents. Still, we cannot exclude the
possibility that P1458L may be a mutation, but in a different
genetic and phenotypic context. In this case, clarification of
the genotype was pivotal for carrier analysis and genetic
counseling of the family.
In family 25, mutation analysis revealed that the father,
despite identical haplotype with the index patient and the
fetus, was not a mutation carrier, neither was the fetus. We
found no evidence for somatic mosaicism in the patient and,
therefore, R1933X represents a de novo mutation in a single
gamete or a germline mosaicism in the father and explains
the, at the time, contradictory findings. This case emphasizes
the importance of mutation detection in preparation for
prenatal diagnosis and screening the COL7A1 gene in a
sample from the affected individual so that de novo mutations
can be identified rather than relying on haplotype data to
determine the status of a fetus at risk. So, while the risk of de
novo mutations is small, here one known de novo mutation
out of 78 alleles (about 1.3%), it is of concern when prenatal
diagnosis is to be performed.
In summary, we established an efficient, sensitive, and
reliable protocol for mutation detection in COL7A1 using a
‘‘priority strategy’’ and direct DNA sequencing, and eluci-
dated the genetic and biological basis of DEB in 41
individuals and families. This analysis emphasized the
complexity of genotypic and phenotypic mechanisms under-
lying DEB and shows that screening for novel COL7A1
mutations must continue for more complete understanding of
the etiopathology of this devastating disease, in particular in
view of development of biologically valid therapeutic
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Figure 2. De novo mutation R1933X in patient 25 with HS-RDEB. Haplotype analysis – based on informative microsatelite markers – of the family shows that
the index patient (II-2, arrow) and her younger sister (II-6) inherited the same haplotypes. As the mutation R1933X (symbolized by þ in the blue haplotype) was
present only in the patient, it occurred de novo. The mother’s third pregnancy was terminated by induced abortion and the forth pregnancy resulted in
spontaneous abortion of twins.
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approaches. For this undertaking, efficient mutation detection
strategies are indispensable.
MATERIALS AND METHODS
Patients
Forty-one patients with clinically and morphologically diagnosed
DEB were investigated. Twenty-four were of Central European
origin, whereas the other patients originated in different regions of
the world. Patients 3, 15, 20, 21, 23, 28, 29, 30, 32, and 34 are
offspring of consanguineous families of Middle Eastern or North
African origin. The patients were referred to the Epidermolysis
bullosa center of the University of Freiburg, or to cooperating centers
(www.netzwerk-eb.de), which provided biopsy material and clinical
information. In most cases, the morphological diagnosis of DEB was
ascertained with antigen mapping, immunofluorescence staining of
blistered DEB skin with antibodies to components of the epithelial
basement membrane zone (Bruckner-Tuderman et al., 1999). In
patients 12, 15, and 20, electron microscopy was performed. In
patient 25, both indirect immunofluorescence and electron micro-
scopy data were available. Following informed consent, EDTA-
blood samples were obtained. The study was approved by the ethical
committees of University of Freiburg and of the cooperating centers.
This study was conducted according to the Declaration of Helsinki
Principles.
Mutation detection strategy
Genomic DNA from index patients and parents was extracted from
EDTA-blood or buccal swabs using QiAmp DNA mini kit (Qiagen,
Hilden, Germany). For amplification of all 118 COL7A1 exons and
exon/intron boundaries, 73 pairs of primers were used (Christiano
et al., 1997), or new primers were designed with frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi software. For mutation detection,
a ‘‘priority strategy’’ based on priority regions was used: COL7A1
exons were classified in three categories according to the number
and frequency of reported mutations (Supplementary material).
Direct sequencing of PCR products was performed using standard
methods, and the samples were analyzed in an ABI prism 3100 (ABI,
Darmstadt, Germany) or Megabace 500 sequencer (Amersham,
Freiburg, Germany). DNA sequences were compared to the
reference sequence from the NCBI Entrez Nucleotide database
(NM_000094, L23982) using the software Mutation Surveyor (Soft-
genetics, www.softgenetics.com). All mutations were confirmed by
resequencing. Parents were investigated if samples were available.
Whenever possible, mutation verification in the index patient and
family members was carried out by restriction endonuclease
digestion according to the manufacturer’s protocols. In case of
novel mutations, 100 control chromosomes were analyzed.
RNA analysis
Total RNA was extracted with QiAmp RNA blood mini kit (Qiagen,
Hilden, Germany) from subconfluent keratinocytes cultivated in
keratinocyte growth medium (Invitrogen, Karlsruhe, Germany).
Reverse transcription was performed with Advantage RT-for-PCR
kit (BD Biosciences, Heidelberg, Germany) with 0.5 mg of total RNA,
using oligo dT primers. For RT-PCR the following primers were used:
Ex24F, 50-GCCACTCAAGACAATGCTCA-30 and Ex28R, 50-TCTGG
CCCTTTGGACAATAC; Ex2F, 50-TGACCTGCACGCGCCTTTACG-30
and Ex4R, 50-CCACAGCAAATAGCTTGACCCC-30.
Indirect immunofluorescence
Indirect immunofluorescence was performed as described (Hamma-
mi-Hauasli et al., 1998). Stained skin cryosections or cells were
visualized with confocal laser scanning microscopy (LSM510, Carl
Zeiss, Germany; 30 mW argon laser at 488 nm) or immunofluores-
cence microscopy (Axiophot, Carl Zeiss, Germany).
Protein analysis
Procollagen VII was extracted from keratinocytes of patients 2 and 7
and immunoblotted (Hammami-Hauasli et al., 1998) using Lumi
Light Western blotting substrate (Roche, Mannheim, Germany).
Limited proteolysis of extracted procollagen VII for determination of
the helix-to-coil transition temperature was performed as described
(Bruckner and Prockop, 1981; Mecklenbeck et al., 2002).
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